150
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Opportunities to boost naloxone awareness among people who misuse opioid analgesics who have not used illegal opioids

, PhD, MPHORCID Icon, , PhD, MHS & , PhD

References

  • Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172–179.
  • Tobin K, Clyde C, Davey-Rothwell M, Latkin C. Awareness and access to naloxone necessary but not sufficient: Examining gaps in the naloxone cascade. Int J Drug Policy. 2018;59:94–97.
  • Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.
  • Behar E, Bagnulo R, Coffin PO. Acceptability and feasibility of naloxone prescribing in primary care settings: a systematic review. Prev Med. 2018;114:79–87.
  • Dunn KE, Barrett FS, Yepez-Laubach C, et al. Brief Opioid Overdose Knowledge (BOOK): a questionnaire to assess overdose knowledge in individuals who use illicit or prescribed opioids. J Addict Med. 2016;10(5):314–323.
  • Huhn AS, Garcia-Romeu AP, Dunn KE. Opioid overdose education for individuals prescribed opioids for pain management: randomized comparison of two computer-based interventions. Front Psychiatry. 2018;9:34.
  • Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–1321.
  • Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92.
  • Muhuri P, Gfroerer J, Davies M. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. 2013. https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm.
  • Fernandez AC, Bush C, Bonar EE, Blow FC, Walton MA, Bohnert A. Alcohol and drug overdose and the influence of pain conditions in an addiction treatment sample. J Addict Med. 2019;13(1):61–68.
  • Gicquelais RE, Mezuk B, Foxman B, Thomas L, Bohnert A. Justice involvement patterns, overdose experiences, and naloxone knowledge among men and women in criminal justice diversion addiction treatment. Harm Reduct J. 2019;16(1):46.
  • Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130(1–2):144–156.
  • Price AM, Ilgen MA, Bohnert A. Prevalence and correlates of nonmedical use of prescription opioids in patients seen in a residential drug and alcohol treatment program. J Subst Abuse Treat. 2011;41(2):208–214.
  • Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: perceptions and use of an evolving drug in baltimore, MD. J Psychoactive Drugs. 2018;50(2):167–176.
  • Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–706.
  • Ravndal E, Amundsen EJ. Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study. Drug Alcohol Depend. 2010;108(1–2):65–69.
  • Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2017. Admissions to and Discharges from Publicly-Funded Substance Use Treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2019. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/TEDS-2017.pdf.
  • Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat. 2013;44(2):241–247.
  • Doe-Simkins M, Bell A. Opioid Overdose Prevention and Related Trauma: Incorporating Overdose Prevention, Response, and Experience into Substance Use Disorder Treatment. Chicago, IL: Illinois Cooccurring Center for Excellence at Heartland Health Outreach; 2014. https://prescribetoprevent.org/wp2015/wp-content/uploads/Incorporating-OD-into-SUD-Tx-12.141.pdf.
  • Dayton L, Gicquelais RE, Tobin K, et al. More than just availability: who has access and who administers take-home naloxone in Baltimore, MD. PLoS One. 2019;14(11):e0224686
  • Binswanger IA, Nowels C, Corsi KF, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7:3.
  • Mueller SR, Koester S, Glanz JM, Gardner EM, Binswanger IA. Attitudes toward naloxone prescribing in clinical settings: a qualitative study of patients prescribed high dose opioids for chronic non-cancer pain. J Gen Intern Med. 2017;32(3):277–283.
  • McCradden MD, Vasileva D, Orchanian-Cheff A, Buchman DZ. Ambiguous identities of drugs and people: a scoping review of opioid-related stigma. Int J Drug Policy. 2019;74:205–215.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.